The estimated Net Worth of Tibor Keler is at least $1.72 Million dollars as of 7 December 2022. Tibor Keler owns over 16,860 units of Celldex Therapeutics stock worth over $1,008,396 and over the last 16 years he sold CLDX stock worth over $0. In addition, he makes $707,353 as Executive Vice President and Chief Scientific Officer at Celldex Therapeutics.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tibor Keler CLDX stock SEC Form 4 insiders trading
Tibor has made over 6 trades of the Celldex Therapeutics stock since 2010, according to the Form 4 filled with the SEC. Most recently he exercised 16,860 units of CLDX stock worth $46,871 on 7 December 2022.
The largest trade he's ever made was exercising 16,860 units of Celldex Therapeutics stock on 7 December 2022 worth over $46,871. On average, Tibor trades about 2,233 units every 194 days since 2009. As of 7 December 2022 he still owns at least 24,217 units of Celldex Therapeutics stock.
You can see the complete history of Tibor Keler stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Tibor Keler biography
Dr. Tibor Keler Ph.D. serves as Executive Vice President and Chief Scientific Officer of the Company. Since May 2003, Dr. Keler has held a number of positions with Celldex, including as a founder, Senior Vice President and Chief Scientific Officer of Celldex, from March 2008 to July 2014, and Vice President, Research and Discovery and Chief Scientific Officer, from May 2003 to March 2008. In addition, he was Senior Director of Preclinical Development and Principal Scientist at Medarex from September 1993 to March 2004. Dr. Keler received his Ph.D. in Microbiology from the University of Pennsylvania.
What is the salary of Tibor Keler?
As the Executive Vice President and Chief Scientific Officer of Celldex Therapeutics, the total compensation of Tibor Keler at Celldex Therapeutics is $707,353. There are 3 executives at Celldex Therapeutics getting paid more, with Ronald Pepin having the highest compensation of $1,225,030.
How old is Tibor Keler?
Tibor Keler is 61, he's been the Executive Vice President and Chief Scientific Officer of Celldex Therapeutics since 2014. There are 13 older and 11 younger executives at Celldex Therapeutics. The oldest executive at Celldex Therapeutics Inc. is Herbert Conrad, 87, who is the Independent Director.
What's Tibor Keler's mailing address?
Tibor's mailing address filed with the SEC is C/O CELLDEX THERAPEUTICS, INC., 53 FRONTAGE ROAD, SUITE 220, HAMPTON, NJ, 08827.
Insiders trading at Celldex Therapeutics
Over the last 16 years, insiders at Celldex Therapeutics have traded over $19,527,314 worth of Celldex Therapeutics stock and bought 273,450 units worth $1,157,166 . The most active insiders traders include Rajesh B Parekh, Garry Arthur Neil, and Inc Medarex. On average, Celldex Therapeutics executives and independent directors trade stock every 69 days with the average trade being worth of $1,750,671. The most recent stock trade was executed by Samuel Bates Martin on 14 June 2024, trading 20,169 units of CLDX stock currently worth $204,917.
What does Celldex Therapeutics do?
celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. our pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response. celldex therapeutics (nasdaq: cldx) was founded based on a fundamental scientific belief that harnessing the power of the immune system would break significant barriers in drug development for a host of devastating diseases. the company's pipeline is comprised of therapeutic antibodies, antibody drug conjugates, immune system modulators and vaccines that we believe have a higher probability of success because they are targeted to specific patient populations with high unmet medical need whose diseases express specific markers, including many underserved or completely un-served orphan indications. this has created a leading pipeline in im
What does Celldex Therapeutics's logo look like?
Complete history of Tibor Keler stock trades at Celldex Therapeutics
Celldex Therapeutics executives and stock owners
Celldex Therapeutics executives and other stock owners filed with the SEC include:
-
Ronald Pepin,
Senior Vice President and Chief Business Officer -
Anthony Marucci,
President, Chief Executive Officer, Director -
Anthony S. Marucci M.B.A.,
Founder, Pres, CEO & Director -
Tibor Keler,
Executive Vice President and Chief Scientific Officer -
Dr. Tibor Keler,
Founder, Chief Scientific Officer & Exec. VP -
Dr. Diane C. Young M.D.,
Sr. VP & Chief Medical Officer -
Margo Heath-Chiozzi,
Senior Vice President - Regulatory Affairs -
Sam Martin,
Chief Financial Officer, Senior Vice President, Secretary -
Richard Wright,
Senior Vice President, Chief Commercial Officer -
Dr. Margo Heath-Chiozzi M.D.,
Sr. VP of Regulatory Affairs -
Elizabeth Crowley,
Senior Vice President, Chief Product Development Officer -
Sam Martin,
Sr. VP, CFO, Sec. & Treasurer -
Elizabeth Crowley,
Chief Product Devel. Officer & Sr. VP -
Karen Shoos,
Independent Chairman of the Board -
Keith Brownlie,
Independent Director -
James Marino,
Independent Director -
Harry Penner,
Independent Director -
Herbert Conrad,
Independent Director -
Diane Young,
Senior Vice President, Chief Medical Officer -
Sarah Cavanaugh,
Senior Vice President - Corporate Affairs and Administration -
Prof. Joseph P. Schlessinger Ph.D.,
Co-Founder & Member of Scientific Advisory Board -
Dr. Richard M. Wright Ph.D.,
Chief Commercial Officer & Sr. VP -
Dr. Ronald A. Pepin,
Chief Bus. Officer & Sr. VP -
Freddy A. Jimenez Esq.,
Sr. VP & Gen. Counsel -
Patrick Till,
Sr. Director of Investor Relations & Corp. Communications -
Sarah Cavanaugh,
Sr. VP of Corp. Affairs & Admin. -
Theresa La Vallee,
SVP, Reg.& Precision Medicine -
Larry Ellberger,
Director -
George Elston,
Director -
Gerald Ph D Mc Mahon,
Director -
Avery W Catlin,
Sr. VP & CFO -
Den Broek Richard Van,
Director -
Rita Jain,
-
Timothy M Shannon,
Director -
Rajesh B Parekh,
Director -
Charles R Schaller,
Director -
Inc Medarex,
10% owner -
Ronald C Newbold,
Sr. VP, Business Dev. -
Cheryl Cohen,
-
Freddy A. Jimenez,
SVP & GENERAL COUNSEL -
Garry Arthur Neil,